AP3592A - Cyclic bridgehead ether dgat1 inhibitors. - Google Patents
Cyclic bridgehead ether dgat1 inhibitors.Info
- Publication number
- AP3592A AP3592A AP2014008018A AP2014008018A AP3592A AP 3592 A AP3592 A AP 3592A AP 2014008018 A AP2014008018 A AP 2014008018A AP 2014008018 A AP2014008018 A AP 2014008018A AP 3592 A AP3592 A AP 3592A
- Authority
- AP
- ARIPO
- Prior art keywords
- bridgehead
- cyclic
- ether
- dgat1 inhibitors
- dgat1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639341P | 2012-04-27 | 2012-04-27 | |
US201361787695P | 2013-03-15 | 2013-03-15 | |
CN2013072735 | 2013-03-15 | ||
PCT/IB2013/053292 WO2013160873A1 (en) | 2012-04-27 | 2013-04-25 | Cyclic bridgehead ether dgat1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2014008018A0 AP2014008018A0 (en) | 2014-10-31 |
AP3592A true AP3592A (en) | 2016-02-15 |
Family
ID=48577190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2014008018A AP3592A (en) | 2012-04-27 | 2013-04-25 | Cyclic bridgehead ether dgat1 inhibitors. |
Country Status (26)
Country | Link |
---|---|
US (2) | US8993619B2 (xx) |
EP (1) | EP2852590B1 (xx) |
JP (1) | JP6042529B2 (xx) |
KR (1) | KR20150013194A (xx) |
CN (1) | CN104395309B (xx) |
AP (1) | AP3592A (xx) |
AR (1) | AR090859A1 (xx) |
AU (1) | AU2013254307B2 (xx) |
BR (1) | BR112014026760A8 (xx) |
CA (1) | CA2870336A1 (xx) |
CL (1) | CL2014002822A1 (xx) |
CO (1) | CO7111275A2 (xx) |
CR (1) | CR20140494A (xx) |
EA (1) | EA025050B1 (xx) |
EC (1) | ECSP14030538A (xx) |
ES (1) | ES2624291T3 (xx) |
IL (1) | IL235313A0 (xx) |
MA (1) | MA37439B1 (xx) |
MX (1) | MX357768B (xx) |
PE (2) | PE20150724A1 (xx) |
PH (1) | PH12014502413A1 (xx) |
SG (1) | SG11201406526WA (xx) |
TN (1) | TN2014000425A1 (xx) |
TW (1) | TW201348239A (xx) |
UY (1) | UY34767A (xx) |
WO (1) | WO2013160873A1 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3243826T3 (da) | 2012-04-26 | 2020-02-03 | Bristol Myers Squibb Co | Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
CN104292190B (zh) * | 2014-09-03 | 2016-05-04 | 哈尔滨工业大学 | 一种β-溴代四氢呋喃类化合物的合成方法 |
CN104292189B (zh) * | 2014-09-03 | 2016-05-04 | 哈尔滨工业大学 | 一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法 |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
EP3853232B1 (en) * | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009081195A1 (en) * | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
WO2012047948A1 (en) * | 2010-10-07 | 2012-04-12 | Novartis Ag | New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
BRPI0410779A (pt) | 2003-05-20 | 2006-06-27 | Novartis Ag | heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma |
CA2575736A1 (en) * | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
NZ571203A (en) * | 2006-03-31 | 2011-12-22 | Novartis Ag | Monocyclic heteroaryl-phenyl-cyclohexyl compounds for treating diseases mediated by DGAT-1 activity |
US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
-
2013
- 2013-04-25 EA EA201491970A patent/EA025050B1/ru not_active IP Right Cessation
- 2013-04-25 SG SG11201406526WA patent/SG11201406526WA/en unknown
- 2013-04-25 CA CA2870336A patent/CA2870336A1/en not_active Abandoned
- 2013-04-25 CN CN201380034256.8A patent/CN104395309B/zh not_active Expired - Fee Related
- 2013-04-25 AU AU2013254307A patent/AU2013254307B2/en not_active Ceased
- 2013-04-25 ES ES13727385.0T patent/ES2624291T3/es active Active
- 2013-04-25 PE PE2014001902A patent/PE20150724A1/es not_active Application Discontinuation
- 2013-04-25 KR KR1020147032910A patent/KR20150013194A/ko not_active Application Discontinuation
- 2013-04-25 JP JP2015507656A patent/JP6042529B2/ja not_active Expired - Fee Related
- 2013-04-25 MX MX2014013002A patent/MX357768B/es active IP Right Grant
- 2013-04-25 EP EP13727385.0A patent/EP2852590B1/en not_active Not-in-force
- 2013-04-25 MA MA37439A patent/MA37439B1/fr unknown
- 2013-04-25 WO PCT/IB2013/053292 patent/WO2013160873A1/en active Application Filing
- 2013-04-25 PE PE2016000359A patent/PE20160802A1/es not_active Application Discontinuation
- 2013-04-25 BR BR112014026760A patent/BR112014026760A8/pt not_active Application Discontinuation
- 2013-04-25 AP AP2014008018A patent/AP3592A/xx active
- 2013-04-26 TW TW102115141A patent/TW201348239A/zh unknown
- 2013-04-26 AR ARP130101409A patent/AR090859A1/es unknown
- 2013-04-26 UY UY0001034767A patent/UY34767A/es not_active Application Discontinuation
- 2013-04-26 US US13/871,586 patent/US8993619B2/en not_active Expired - Fee Related
-
2014
- 2014-10-13 TN TN2014000425A patent/TN2014000425A1/fr unknown
- 2014-10-20 CL CL2014002822A patent/CL2014002822A1/es unknown
- 2014-10-23 IL IL235313A patent/IL235313A0/en unknown
- 2014-10-27 CO CO14237492A patent/CO7111275A2/es active IP Right Grant
- 2014-10-27 CR CR20140494A patent/CR20140494A/es unknown
- 2014-10-27 PH PH12014502413A patent/PH12014502413A1/en unknown
- 2014-11-27 EC ECIEPI201430538A patent/ECSP14030538A/es unknown
-
2015
- 2015-02-20 US US14/628,205 patent/US20150166563A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009081195A1 (en) * | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
WO2012047948A1 (en) * | 2010-10-07 | 2012-04-12 | Novartis Ag | New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid |
Non-Patent Citations (1)
Title |
---|
BIRCH A M ET AL: "Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 52, 26 March 2009 (2009-03-26), pages 1558 - 1568, XP002586908 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3592A (en) | Cyclic bridgehead ether dgat1 inhibitors. | |
HK1212984A1 (zh) | 咪唑並吡啶化合物 | |
GB2501897B (en) | Injection devices | |
GB201317141D0 (en) | Well Isolation | |
EP2803217A4 (en) | geolocation | |
EP2813437A4 (en) | BOTTLE | |
HK1201484A1 (en) | Injection devices | |
GB2507645B (en) | Collet | |
HK1180931A1 (en) | An electro-pulsograph | |
AU342825S (en) | Bottle | |
EP2821349A4 (en) | BOTTLE | |
GB201219753D0 (en) | Injection devices | |
ZA201408478B (en) | Bottle | |
GB201903206D0 (en) | n | |
HK1214576A1 (zh) | 改進的瓶子 | |
EP2906492A4 (en) | ROPE WINDING DEVICE | |
AP00465S1 (en) | Bottle | |
GB201304888D0 (en) | Improved bottle | |
AU345908S (en) | Bottle | |
AP00422S1 (en) | Bottle case | |
AU347603S (en) | Bottle | |
AU347602S (en) | Bottle | |
AU345690S (en) | Bottle | |
AU346628S (en) | Bottle | |
GB201218525D0 (en) | Bi-Vi bottle |